Anorexia News and Research RSS Feed - Anorexia News and Research

Positive emotions may play exacerbating role in fueling anorexia nervosa

Positive emotions may play exacerbating role in fueling anorexia nervosa

Positive emotions - even those viewed through a distorted lens - may play an exacerbating role in fueling eating disorders like anorexia nervosa, which has a death rate 12 times higher for females between the ages of 15 and 24 than all other causes of death combined, according to a Rutgers study. [More]
Childhood obesity linked to early puberty

Childhood obesity linked to early puberty

A new link has been identified between obesity in childhood and the lowering of the age of puberty. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
High level of adiponectin linked to decreased risk of diabetes, cardiovascular disease

High level of adiponectin linked to decreased risk of diabetes, cardiovascular disease

It has been known for its flavorful addition to soups and as a delicacy for dogs but bone marrow fat may also have untapped health benefits, new research finds. [More]
CHOP study: Children with specific gene variants may require higher doses of pain-control drugs

CHOP study: Children with specific gene variants may require higher doses of pain-control drugs

In the first genome-wide analysis of postsurgical pain in children, pediatric researchers identified variations in genes that affect a child's need for pain-control drugs. The findings suggest that at some point physicians may calibrate pain-medication dosages according to a child's individual genetic makeup. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç. [More]

Research finds food addicts lacking psychological inhibition

Women with weight problems were more impulsive than average in a food-related psychology test, a new research paper has shown. [More]
Emily Program plans to open new office in Olympia

Emily Program plans to open new office in Olympia

The Emily Program - a nationally recognized eating disorder treatment center- today announced plans to open a new office in Olympia, WA, its 3rd location in the Seattle area, 4th location in the Pacific Northwest. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
RDT receives FDA approval for new liquid form of treatment for patients with ALL

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL). [More]
Oral health: The gateway to your overall health

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health. [More]
UT Southwestern researchers identify potential new treatment for depression

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression. [More]
Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA). [More]
Brain disconnect leaves teen brain less able to judge trustworthiness

Brain disconnect leaves teen brain less able to judge trustworthiness

Making a snap decision usually means following your initial reaction -- going with your gut. That intuitive feeling sprouts from the limbic system, the evolutionarily older and simpler part of the brain that affects emotion, behavior and motivation. [More]
Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. [More]

GW SPHHS to hold public forum on prevalence and impact of eating disorders

The George Washington (GW) University School of Public Health and Health Services (SPHHS) will hold a public forum on February 25 that will address the prevalence and impact of eating disorders, especially on college campuses. [More]
Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La. [More]
Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative. [More]
Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease. [More]